Regulus Therapeutics (NASDAQ:RGLS) Given “Buy” Rating at Canaccord Genuity Group

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reissued by equities researchers at Canaccord Genuity Group in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $28.00 price objective on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Friday. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Regulus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $12.75.

Regulus Therapeutics Stock Performance

Shares of Regulus Therapeutics stock traded down $0.03 on Monday, reaching $1.45. 24,007 shares of the company’s stock were exchanged, compared to its average volume of 520,879. Regulus Therapeutics has a 52 week low of $0.83 and a 52 week high of $3.00. The firm’s 50-day moving average is $1.28 and its two-hundred day moving average is $1.46. The company has a market capitalization of $94.98 million, a P/E ratio of -1.36 and a beta of 1.42.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). During the same period in the prior year, the firm earned ($0.40) earnings per share. On average, analysts expect that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Buying and Selling at Regulus Therapeutics

In other Regulus Therapeutics news, CFO Crispina Calsada sold 38,716 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the transaction, the chief financial officer now owns 50,566 shares in the company, valued at $63,713.16. This trade represents a 43.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joseph P. Hagan sold 115,290 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the transaction, the chief executive officer now owns 222,572 shares of the company’s stock, valued at approximately $280,440.72. This represents a 34.12 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 223,998 shares of company stock worth $282,237. Corporate insiders own 4.35% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in Regulus Therapeutics in the 3rd quarter worth about $46,000. PEAK6 LLC bought a new position in Regulus Therapeutics in the 4th quarter worth about $95,000. Velan Capital Investment Management LP bought a new position in Regulus Therapeutics in the 4th quarter worth about $111,000. JPMorgan Chase & Co. boosted its position in shares of Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 62,549 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.